Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon

Journal of Hepatology

Volumn 30, Issue 5, 1999, Pages 783-787

  Reichard, Olle ^a   Glaumann, Hans ^b   Frydén, Aril ^c   Norkrans, Gunnar ^d   Wejstål, Rune ^d   Weiland, Ola ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Follow up; Histological; Interferon therapy; Long term; Virological

Indexed keywords

ALFANATIVE; ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033058754     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80129-9     Document Type: Article

References (32)

1. Hoofnagle JH, Mullen KD, Jones B, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha-interferon. N Engl J Med. 315:1986;1575-1578.
2. National Institutes of Health consensus development conference panel statement: management of hepatitis C. Hepatology. 26:1997;2S-10S.
3. Davis G, Balart L, Schiff E, Linsday K, Bodenheimer H, Perillo R, et al. the Hepatitis Interventional Therapy Group . Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med. 321:1989;1501-1506.
4. Di Bisceglie A, Martin P, Kassianides C, Lisker-Melman M, Murray L Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebocontrolled trial. N Engl J Med. 321:1989;1506-1510.
5. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, et al. the TriVeneto viral hepatitis group . Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology. 22:1995;700-706.
6. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. the Multicenter Study Group . A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med. 332:1995;1457-1462.
7. Chemello L, Cavalletto L, Donada C, Bonetti P, Casarin P, Urban F, et al. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology. 113:1997;1654-1659.
8. Camps J, Garcia N, Rieza-Boj J, Civiera M, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol. 19:1993;408-412.
9. Brillianti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology. 107:1994;812-817.
10. Schvarcz R, Ando Y, Sönnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol. 23:(suppl 2):1995;17-21.
11. Palmer Smith J. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci. 42:1997;1681-1687.
12. Reichard O, Glaumann H, Norkrans G, Wejstål R, Frydén A, Schvarcz R, et al. Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course. Liver. 14:1994;169-174.
13. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon alfa-2b. Hepatology. 18:1993;1300-1305.
14. Shindo M, Di Bisceglie A, Cheung L, Wai-Kuo Shih J, Cristiano K, Feinstone S, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 115:1991;700-704.
15. Romeo R, Pol S, Berthelot P, Brechot C. Eradication of hepatitis C virus RNA after alpha-interferon therapy. Ann Intern Med. 121:1994;276-277.
16. Reichard O, Glaumann H, Frydén A, Norkrans G, Schvarcz R, Sönnerborg A, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology. 21:1995;918-922.
17. Tsubota A, Kumada H, Chayama K, Arase Y, Saitoh S, Koida I, et al. Time course of histological changes in patients with sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection. J Hepatol. 27:1997;49-55.
18. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 127:1997;875-881.
19. Camma C, Di Marco V, Lo Iacono O, Almasio P, Giunta M, Fuschi P, et al. Long-term course of interferon-treated chronic hepatitis C. J Hepatol. 28:1998;531-537.
20. Schvarcz R, Weiland O, Wejstål R, Norkrans G, Fryden A, Foberg U. A randomised controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies. Scand J Infect Dis. 21:1989;617-625.
21. Reichard O, Foberg U, Frydén A, Mattsson L, Norkrans G, Sönnerborg A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C following treatment with interferon alpha-2b for 60 weeks. Hepatology. 19:1994;280-285.
22. Weiland O, Chen M, Lindh G, Mattsson L, Schvarcz R, Sönnerborg A, et al. Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection. Scand J Infect Dis. 27:1995;319-324.
23. Yun ZB, Lindh G, Weiland O, Johansson B, Sönnerborg A. Detection of hepatitis C virus (HCV) RNA by PCR related to HCV antibodies in serum and liver histology in Swedish blood donors. J Med Virol. 39:1993;57-61.
24. Young KK, Resnick RM, Myers TW. Detection of hepatitis virus C RNA by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol. 31:1993;882-886.
25. Yun Z, Lundeberg J, Johansson B, Hedrum A, Weiland O, Uhlén M, et al. Colorimetric detection of competitive PCR products for quantification of hepatitis C viremia. J Virol Methods. 47:1994;1-14.
26. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol. 73:1992;673-679.
27. Widell A, Shev S, Månsson S, Zhang Y, Foberg U, Norkrans G, et al. Genotyping of hepatitis C virus isolates by a modified PCR assay using type type-specific primers: epidemiological applications. J Med Virol. 44:1994;272-279.
28. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 13:1991;372-374.
29. Lindsay KL. Therapy of hepatitis C: overview. Hepatology. 26:1997;71S-77S.
30. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 27:1998;209-212.
31. Davis G, Balart L, Schiff E, Lindsay K, Bodenheimer H, Perillo R, et al. Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile. Clin Ther. 16:1994;334-343.
32. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effect of interferon-alfa on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 346:1995;1051-1055.